Talphera (TLPH) Income from Continuing Operations (2010 - 2026)
Talphera (TLPH) posted quarterly Income from Continuing Operations of 3897000.0 for Q1 2026, down 36.88% year-over-year from 6174045.08 in Q1 2025, and up 94.85% quarter-over-quarter from 75737000.0 in Q4 2025.
Talphera (TLPH) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Talphera's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 3897000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 36.88% year-over-year to 3897000.0; the TTM figure through Mar 2026 stood at 86811000.0 (down 561.67% YoY), while the FY2025 annual figure was 85535000.0, up 27.23% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 3897000.0, up from 75737000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 74315000.0 in Q2 2022, with the low at 75737000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 3827000.0 (2024), against an average of 4279882.35.
- Peak annual rise in Income from Continuing Operations reached 854.39% in 2022, while the deepest fall reached 2843.54% in 2022.
- Talphera's Income from Continuing Operations stood at 15954000.0 in 2022, then jumped by 56.12% to 7000000.0 in 2023, then soared by 55.81% to 3093000.0 in 2024, then plunged by 2348.66% to 75737000.0 in 2025, then jumped by 94.85% to 3897000.0 in 2026.
- Business Quant data shows TLPH's Income from Continuing Operations at 3897000.0 in Q1 2026, 75737000.0 in Q4 2025, and 3567000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Talphera | 90.25 Mn | 90.25 Mn | - | -3.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.42 Mn |
| Mar 31, 2026 | -3.90 Mn |
| Dec 31, 2025 | -75.74 Mn |
| Sep 30, 2025 | -3.57 Mn |
| Jun 30, 2025 | -3.61 Mn |
| Mar 31, 2025 | -2.85 Mn |
| Dec 31, 2024 | -3.09 Mn |
| Sep 30, 2024 | -3.35 Mn |
| Jun 30, 2024 | -3.83 Mn |
| Mar 31, 2024 | -4.02 Mn |
| Dec 31, 2023 | -7.00 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | -4.43 Mn |
| Mar 31, 2023 | -329,000.00 |
| Dec 31, 2022 | -15.95 Mn |
| Sep 30, 2022 | -4.64 Mn |
| Jun 30, 2022 | 74.32 Mn |
| Mar 31, 2022 | -9.36 Mn |
| Dec 31, 2021 | -542,000.00 |
| Sep 30, 2021 | -8.38 Mn |